Lewerin Catharina, Ljunggren Östen, Nilsson-Ehle Herman, Karlsson Magnus K, Herlitz Hans, Lorentzon Mattias, Ohlsson Claes, Mellström Dan
Section of Hematology and Coagulation, Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden.
Department of Medical Sciences, University of Uppsala, Uppsala, Sweden.
Bone. 2017 May;98:1-8. doi: 10.1016/j.bone.2017.02.005. Epub 2017 Feb 14.
Fibroblast growth factor (FGF23) is a protein that is produced by osteoblasts and osteocytes. Increased serum levels of FGF23 have been associated with increased risks of osteoporotic fractures and cardiovascular disease, particularly in participants with poor renal function. Serum iron (Fe) has been suggested as a regulator of FGF23 homeostasis.
To determine whether Fe and iron status are determinants of the levels of intact FGF23 (iFGF23) in elderly men.
The MrOS study is a population-based study of elderly men (N=1010; mean age, 75.3years; range, 69-81years). The levels of Fe, transferrin saturation (TS), and ferritin were evaluated in relation to the serum concentrations of iFGF23 before and after adjustments for confounders.
TS <15% was found in 3.5% (34/977) of the participants, who had a higher median level iFGF23 compared with the remaining subjects (47.4μmol/L vs. 41.9μmol/L, p=0.008). The levels of iFGF23 correlated negatively (un-adjusted) with the levels of Fe (r=-0.17, p<0.001), TS (r=-0.16, p<0.001) and serum ferritin (r=-0.07, p=0.022). In addition, in participants with estimated glomerular filtration rate eGFRCystatin C>60mL/min, the levels of iFGF23 correlated (age-adjusted) negatively with the levels of Fe (r=-0.15, p<0.001) and TS (r=-0.17, p<0.001). The level of iFGF23 correlated positively (un-adjusted) with lumbar spine bone mineral density (BMD) (r=0.14, p<0.001), total body BMD (r=0.11, p=0.001), and total hip BMD (r=0.09, p=0.004). The corresponding correlations, when adjusted for age, weight, and height were: r=0.08, p=0.018; r=0.05, p=0.120; and r=0.02, p=0.624, respectively. No associations were found between BMD and the levels of Fe or TS. Multiple step-wise linear regression analyses [adjusting for age, body mass index (BMI), comorbidity index, cystatin C, C-reactive protein (hs-CRP), serum vitamin D 25-OH (25OHD), phosphate, calcium, parathyroid hormone (PTH), erythropoietin, hemoglobin, lumbar spine BMD, apolipoprotein B/A1 ratio] were performed in three separate models with Fe, TS or ferritin as potential explanatory variables. Fe and TS, but not ferritin, were independent predictors of iFGF23 level (standardized β-values: -0.10, p<0.001; -0.10, p<0.001; and -0.05, p=0.062, respectively).
Low levels of Fe in elderly men are associated with high levels of iFGF23, independently of markers of inflammation and renal function, suggesting an iron-related pathway for FGF23 regulation.
成纤维细胞生长因子(FGF23)是一种由成骨细胞和骨细胞产生的蛋白质。血清FGF23水平升高与骨质疏松性骨折和心血管疾病风险增加有关,尤其是在肾功能较差的参与者中。血清铁(Fe)被认为是FGF23稳态的调节因子。
确定铁和铁状态是否为老年男性中完整FGF23(iFGF23)水平的决定因素。
MrOS研究是一项基于人群的老年男性研究(N = 1010;平均年龄75.3岁;范围69 - 81岁)。在对混杂因素进行调整前后,评估铁、转铁蛋白饱和度(TS)和铁蛋白水平与iFGF23血清浓度的关系。
3.5%(34/977)的参与者TS<15%,与其余受试者相比,这些参与者的iFGF23中位数水平更高(47.4μmol/L对41.9μmol/L,p = 0.008)。iFGF23水平与铁水平(r = -0.17,p<0.001)、TS(r = -0.16,p<0.001)和血清铁蛋白(r = -0.07,p = 0.022)呈负相关(未调整)。此外,在估计肾小球滤过率eGFRCystatin C>60mL/min的参与者中,iFGF23水平与铁水平(r = -0.15,p<0.001)和TS(r = -0.17,p<0.001)呈负相关(年龄调整后)。iFGF23水平与腰椎骨密度(BMD)(r = 0.14,p<0.001)、全身BMD(r = 0.11,p = 0.001)和全髋BMD(r = 0.09,p = 0.004)呈正相关(未调整)。在调整年龄、体重和身高后,相应的相关性分别为:r = 0.08,p = 0.018;r = 0.05,p = 0.120;r = 0.02,p = 0.624。未发现BMD与铁或TS水平之间存在关联。以铁、TS或铁蛋白作为潜在解释变量,在三个独立模型中进行了多步线性回归分析[调整年龄、体重指数(BMI)、合并症指数、胱抑素C、C反应蛋白(hs-CRP)、血清维生素D 25-OH(25OHD)、磷酸盐、钙、甲状旁腺激素(PTH)、促红细胞生成素、血红蛋白、腰椎BMD、载脂蛋白B/A1比值]。铁和TS是iFGF23水平的独立预测因子,但铁蛋白不是(标准化β值分别为:-0.10,p<0.001;-0.10,p<0.001;-0.05,p = 0.062)。
老年男性铁水平低与iFGF23水平高相关,独立于炎症和肾功能标志物,提示存在与铁相关的FGF23调节途径。